- ÍøÕ¾Ê×Ò³
- ¹ØÓÚ97¹ú¼Ê
- ²úÆ·ÖÐÐÄ
- Ñо¿¿ª·¢
- ÐÂÎÅ×ÊѶ
- ÈËÁ¦×ÊÔ´
- ÁªÏµ97¹ú¼Ê
- English
¿ªÍØÁ¢Ò졤¹ØÁµÈËÉú
97¹ú¼ÊÖÆÒ©¼¯ÍÅ¡ª×¨Òµ´ÓÊÂÏÖ´úÖÐÒ©¡¢»¯Ñ§ÖÊÁÏÒ©¼°ÆäÖƼÁÑз¢¡¢Éú²úºÍÏúÊ۵ĸßÐÂÊÖÒÕÆóÒµ
ϲѶ | 97¹ú¼ÊÖÆÒ©¼¯ÍŸ»ÂíËá±û·ÓÌæŵ¸£Î¤»¯Ñ§ÖÊÁÏÒ©×¢²áÉêÇë»ñÅú£¡
- ·ÖÀࣺÐÂÎÅ×ÊѶ
- ×÷Õߣº
- ȪԴ£º
- ÈÕÆÚ£º2024Äê03ÔÂ02
- »á¼ûÁ¿£º0
¡¾ÌáÒªÐÎò¡¿¿ËÈÕ£¬97¹ú¼ÊÊÕµ½¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÅú׼ǩ·¢µÄ¹ØÓÚÖÊÁÏÒ©¸»ÂíËá±û·ÓÌæŵ¸£Î¤µÄ¡¶»¯Ñ§ÖÊÁÏÒ©ÉÏÊÐÉêÇëÅú׼֪ͨÊé¡· ¡£
ϲѶ | 97¹ú¼ÊÖÆÒ©¼¯ÍŸ»ÂíËá±û·ÓÌæŵ¸£Î¤»¯Ñ§ÖÊÁÏÒ©×¢²áÉêÇë»ñÅú£¡
¡¾ÌáÒªÐÎò¡¿¿ËÈÕ£¬97¹ú¼ÊÊÕµ½¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÅú׼ǩ·¢µÄ¹ØÓÚÖÊÁÏÒ©¸»ÂíËá±û·ÓÌæŵ¸£Î¤µÄ¡¶»¯Ñ§ÖÊÁÏÒ©ÉÏÊÐÉêÇëÅú׼֪ͨÊé¡· ¡£
- ·ÖÀࣺÐÂÎÅ×ÊѶ
- ×÷Õߣº
- ȪԴ£º
- ÈÕÆÚ£º2024-03-02
- »á¼ûÁ¿£º0
ÏêÇé
¿ËÈÕ£¬97¹ú¼ÊÊÕµ½¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÅú׼ǩ·¢µÄ¹ØÓÚÖÊÁÏÒ©¸»ÂíËá±û·ÓÌæŵ¸£Î¤µÄ¡¶»¯Ñ§ÖÊÁÏÒ©ÉÏÊÐÉêÇëÅú׼֪ͨÊé¡· ¡£
¹ØÓÚ¸»ÂíËá±û·ÓÌæŵ¸£Î¤
¸»ÂíËá±û·ÓÌæŵ¸£Î¤£¨TAF£©£¬ÊÇÒ»ÖÖÖÎÁƳÉÈ˺ÍÇàÉÙÄ꣨12ËêÒÔÉÏ£¬ÌåÖØÖÁÉÙΪ35kg£©ÂýÐÔÒÒÐ͸ÎÑ×£¨HBV£©µÄÇ¿¿¹²¡¶¾Ò©Îï ¡£Æ¾Ö¤ÃÀ¹úAASLD¡¶ÂýÐÔÒÒÐ͸ÎÑ×Ô¤·À¡¢Õï¶ÏºÍÖÎÁÆ£¨2018Ä꣩¡·¡¢ÖлªÒ½Ñ§»á¡¶ÂýÐÔÒÒÐ͸ÎÑ×ϲãÕïÁÆÖ¸ÄÏ£¨2020Ä꣩¡·¡¢¡¶ÂýÐÔÒÒÐ͸ÎÑ×·ÀÖÎÖ¸ÄÏ£¨2019Äê°æ£©¡·µÈº£ÄÚÍâȨÍþÖ¸ÄϾùÍƼö¸»ÂíËá±û·ÓÌæŵ¸£Î¤ÖƼÁ×÷ΪÖÎÁÆÂýÐÔÒÒÐ͸ÎÑ×µÄÁÙ´²Ò»Ïß¿¹²¡¶¾ÖÎÁÆÓÃÒ©Ö®Ò» ¡£
¸»ÂíËá±û·ÓÌæŵ¸£Î¤ÊǸ»ÂíËáÌæŵ¸£Î¤¶þßÁß»õ¥µÄÉý¼¶°æ£¬Õ½Ê¤Á˲¿·Ö¸»ÂíËáÌæŵ¸£Î¤¶þßÁß»õ¥µÄÈõµã£¬ÆäÇå¾²ÐÔºÍÓÐÓÃÐÔ¾ù¸ßÓÚºóÕß ¡£¸»ÂíËá±û·ÓÌæŵ¸£Î¤½Ï¸»ÂíËáÌæŵ¸£Î¤¶þßÁß»õ¥Ï¸°ûÄÚÒ©ÎïŨ¶È¸ß5.3±¶£¬Ñª½¬ÄÚÒ©ÎïŨ¶ÈµÍ91% ¡£ÓëÔÚѪ½¬ÖпìËÙË®½âΪÌæŵ¸£Î¤µÄÌæŵ¸£Î¤õ¥£¨TDF£©Ïà±È£¬TAFÔÚѪ½¬ÖÐÌåÏÖ³ö¸ü¸ßµÄÎȹÌÐÔ£¬²¢ÔÚ°Ðϸ°ûÖеִï¸ü¸ßµÄϸ°ûÄÚˮƽ ¡£¾Ý±¨µÀ£¬TAFÔÚ±ÈTDFµÍÊ®±¶µÄ¼ÁÁ¿Ï±¬·¢¸ü¸ßµÄ¿¹²¡¶¾Ð§¹û£¬¶ÔÉö¹¦Ð§ºÍ¹ÇÃܶȵÄÓ°Ïì½ÏС ¡£
¹ØÓÚ97¹ú¼ÊÖÆÒ©¼¯ÍÅ
97¹ú¼ÊÖÆÒ©¼¯ÍÅʼ´´ÓÚ1970Ä꣬×ܲ¿Î»ÓÚÕã½ÎÂÁ룬ÊÇÒ»¼Òרҵ´ÓÊÂÏÖ´úÖÐÒ©¡¢»¯Ñ§ÖÊÁÏÒ©¼°ÖƼÁÑз¢¡¢Éú²úºÍÏúÊ۵ĸßÐÂÊÖÒÕÆóÒµ ¡£¶àÄêÀ´£¬¹«Ë¾Ê¼ÖÕ¼á³Ö×ß²úѧÑÐÒ»Ì廯õ辶£¬ÉèÓгÉÊìµÄÊÖÒÕת»¯Æ½Ì¨£¬Öصã½á¹¹ÐÄÄÔѪ¹Ü¡¢Éñ¾ÏµÍ³µÈ¼²²¡ÁìÓò£¬ÏÖÔÚÒÑÐγɓÒÔ×ÔȻֲÎïҩΪÌØÉ«£¬ÒÔÐÄÄÔѪ¹ÜºÍÉñ¾ÏµÍ³ÓÃҩΪÖ÷£¬ºôÎüϵͳ¼°ÆäËûÁìÓòÓÃҩΪ¸¨”µÄ²úÆ·ÃûÌ㬲¢ÓµÓÐÁ½´óȫ֪ʶ²úȨ²úÆ·——ÒøÐÓÒ¶µÎÍ衢ʯɼ¼î¼××¢ÉäÒº ¡£
¡¾²Î¿¼ÎÄÏס¿
[1] Mills A, Crofoot G Jr, McDonald C, Shalit P, Flamm JA, Gathe J Jr, Scribner A, Shamblaw D, Saag M, Cao H, Martin H, Das M, Thomas A, Liu HC, Yan M, Callebaut C, Custodio J, Cheng A, McCallister S. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study. J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):439-45. doi: 10.1097/QAI.0000000000000618. PMID: 25867913.
[2] Ray AS, Fordyce MW, Hitchcock MJ. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. Antiviral Res. 2016 Jan;125:63-70. doi: 10.1016/j.antiviral.2015.11.009. Epub 2015 Nov 27. PMID: 26640223.
[3] Li X, Tan XY, Cui XJ, Yang M, Chen C, Chen XY. Pharmacokinetics of Tenofovir Alafenamide Fumarate and Tenofovir in the Chinese People: Effects of Non-Genetic Factors and Genetic Variations. Pharmgenomics Pers Med. 2021 Oct 14;14:1315-1329. doi: 10.2147/PGPM.S329690. PMID: 34703277; PMCID: PMC8525415.
[4] ÎâСÑÞ,ÓÚºÆ,ÖÜÑó,µÈ. ¸»ÂíËá±û·ÓÌæŵ¸£Î¤Ó븻ÂíËáÌæŵ¸£Î¤¶þßÁß»õ¥¶ÔѪ֬ӰÏìµÄmetaÆÊÎö[J]. Ò©Îï²»Á¼·´Ó¦ÔÓÖ¾,2021,23(11):584-591. DOI:10.3760/cma.j.cn114015-20211013-01064.
ɨ¶þάÂëÓÃÊÖ»ú¿´
Ïà¹ØÍƼö
2025-11-04
97¹ú¼ÊÈ«ÇòÊ×´´ÖØ°õÐÂÒ©WP103ÒýÁìÐÂÉú¶ùÄÔ²¡ÖÎÁƸïÃüÐÔÍ»ÆÆ
ÿһ¸öÐÂÉúÃüµÄ½µÁÙ£¬¶¼³ÐÔØ׿ÒÍ¥µÄÆÚÅÎÓëÃÎÏë ¡£È»¶ø£¬ÐÂÉú¶ùȱÑõȱѪÐÔÄÔ² ¡£¨HIE£©È´ËÆÒ»µÀÎÞÇéµÄÒõö²£¬Íþв×ÅÈ«ÇòÊý°ÙÍòÐÂÉú¶ùµÄ¿µ½¡ ¡£ÃæÁÙÕâÒ»ÌìÏÂÐÔҽѧÄÑÌ⣬97¹ú¼ÊʼÖռ縺¡°Á¢ÒìÊØ»¤ÉúÃü¡±µÄʹÃü ¡£´Ë´Î£¬¸Ã¹«Ë¾Ðû²¼£¬Æä×ÔÖ÷Ñз¢µÄÁ¢ÒìÒ©WP103ÔÚÕë¶ÔHIEµÄÖÎÁÆÁìÓò£¬È¡µÃÁËÕðº³Òµ½çµÄÀï³Ì±®Ê½Ï£Íû£¡
Éó²éÏêÇé
2025-11-04
97¹ú¼ÊÖÆÒ©WP203A»ñÃÀ¹úFDAÊÚÓèÖÎÁÆÌìðå´¯µÄ¹Â¶ùÒ©È϶¨
¿ËÈÕ£¬97¹ú¼ÊÖÆÒ©ÔÚÑÐÐÂÒ©WP203A£¨°¢·¨ÅµëÄ£¬afamelanotide£©»ñµÃÃÀ¹úFDAÊÚÓèµÄÖÎÁÆÌìðå´¯£¨pemphigus£©µÄ¹Â¶ùÒ©×ʸñÈ϶¨ ¡£ÈÏÕæÈËÕԹڼײ©Ê¿ÌåÏÖ£¬¡°ÏÖÔÚÎÒÃÇÕýÆð¾¢ÍƽøWP203AÔÚÈ«Çò¹æÄ£µÄÐÂÒ©¿ª·¢£¬ÆÚ´ý¸ü¶àµÄÌìðå´¯»¼ÕßÄܹ»ÔçÈÕÓÃÉÏÕâһеÄÖÎÁÆÑ¡Ôñ ¡£¡±
Éó²éÏêÇé
2025-11-04
97¹ú¼ÊÔÑÐÒ©MCR»·ëÄ¿ª·¢ÌÇÄò²¡ÊÓÍøĤ²¡±ä¶àͨ·ÖÎÁÆÐÂÕ½ÂÔ£¬Í»ÆÆ¿¹VEGFÒ©Îï¾ÖÏÞ½ø¾üDZÔÚÊý°ÙÒÚÐÂÈüµÀ
ÌÇÄò²¡ÊÓÍøĤ²¡±ä£¨DR£©ÊÇÌÇÄò²¡×î³£¼ûÇÒÑÏÖصÄ΢Ѫ¹Ü²¢·¢Ö¢Ö®Ò»£¬Ò²ÊǸ÷ÄêËêÈËȺ£¨°üÀ¨¶ùͯ¡¢ÊÂÇé³ÉÄêÈ˺ÍÍíÄêÈË£©Ö÷ÒªµÄÖÂäԵ¹ÊÔÓÉ1 ¡£2020Ä꣬ȫÇòÓÐÁè¼Ý1.03ÒÚÈËÊܵ½ÌÇÄò²¡ÊÓÍøĤ²¡±äµÄÓ°Ï죬Ԥ¼Æµ½2045ÄêÕâÒ»Êý×Ö½«ÉÏÉýµ½1.61ÒÚÈË1 ¡£ÕâÒ»ÑÓÐø¶àÄêµÄÁÙ´²ðó¼²£¬Õý±»Ò»ÏîÖйúÔ´´Í»ÆÆËùº³¶¯ ¡£¿ËÈÕ£¬¾ÝϤ97¹ú¼Ê£¨ÒÔϼò³Æ¡°97¹ú¼Ê¡±£©×ÔÖ÷Ñз¢µÄÁ¢ÒìС·Ö×Ó»·ëÄÒ©ÎMCR»·ëÄ£©ÔÚÌÇÄò²¡ÊÓÍøĤ²¡±äÖÎÁÆÁìÓòÈ¡µÃÁÙ´²Ç°ÖØ´óÍ»ÆÆ ¡£
Éó²éÏêÇé
